Back

Effect of LOX-1 inhibition on coronary atherosclerosis among patients with residual inflammation after myocardial infarction

31 August 2025 (11:00 - 11:15)
Organised by: Logo
Congress Presentation Part of: Nature Medicine: 2025 highlights Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Michelle O'Donoghue

Brigham and Women's Hospital, Boston (United States of America)

3 More presentations in this session

Presentation thumbnail
Phase 1 trial of a monoclonal antibody targeting the angiopoietin-like protein 3/8 complex in patients with mixed hyperlipidaemia
Doctor D. Gaudet (Montreal, CA)
Slides Video
Presentation thumbnail
Effects of vutrisiran on echocardiographic measures of cardiac structure and function: the HELIOS-B trial
Doctor K. Jering (Boston, US)
Slides Video
Presentation thumbnail
Endothelial cell-related genetic variants identify LDL cholesterol-sensitive individuals who derive greater benefit from aggressive lipid-lowering
Doctor N. Marston (Boston, US)
Slides Video

Access the full session

Session thumbnail
Nature Medicine: 2025 highlights
Video

The Event

Event poster

ESC Congress 2025

31 August 2025 11:00 CET
You may be interested in
thumbnail
Congress Session
Smaller trials and other studies on atherosclerosis
1 September 2024
thumbnail
Congress Presentation
Biomarker-guided risk management following acute coronary syndromes
30 August 2025
thumbnail
Congress Presentation
TADCLOT- Twice A Day CLOpidogrel vs. Ticagrelor post STEMI
30 August 2025
thumbnail
Congress Session
Late-breaking science on pharmacology
28 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources